HiSiaddi is an innovative foreign trade service provider driven by dual engines of technology transformation and foreign trade services. We have established a service system formulated as "1+2+3+4=1" and can supply original factory goods of well-known brands for P29, the core intermediate of semaglutide. As an R&D-oriented foreign trade service provider, HiSiaddi has repeatedly resolved customized product demands for P29 by leveraging technological transformation cooperation with manufacturers and precise insight into market demands. Below is the case of HiSiaddi addressing customized requirements for P29.
For further customized service inquiries, please contact HiSiaddi customer service.
The client is BioPharma Zurich AG, a world-leading biopharmaceutical enterprise based in Zurich, Switzerland. It focuses on the R&D and commercialization of GLP-1 hypoglycemic and weight-loss innovative drugs, with products supplied to mainstream medical institutions across Europe and America. The company adheres to the highest standards including FDA, EMA, ICH Q7 and GMP. Its core product is long-acting semaglutide analogs, with an annual demand of 150 kg of P29 (Arg34GLP-1(9-37)) intermediate, classifying it as a high-end overseas client.
· Extreme purity: HPLC purity ≥99.5%, single impurity ≤0.1%, total impurities ≤0.5% (surpassing the mainstream 98% standard in the market)
· Strict impurity control: Host protein <10 ng/mg, endotoxin <0.1 EU/mg, animal-origin-free, bacteriophage-free
· Customized specifications: Sterile lyophilized powder, 1 kg per vial, -20°C light-shielded packaging, full English DMF/COA documents
· Process confidentiality: Exclusive fermentation-purification production line without co-production with other clients, provision of Process Validation (PV) reports
· Delivery timeline: First batch of 50 kg delivered within 45 days (conventional cycle exceeds 60 days)
Local European suppliers charge a 40% premium and suffer insufficient production capacity. Three regular domestic manufacturers stated they could not simultaneously meet the requirements of high purity, low endotoxin, sterile customization and confidential production lines. They could only supply standard 98% purity products unable to pass FDA audits, putting the customized project at risk of suspension. The client urgently entrusted HiSiaddi to lock customized production capacity, optimize processes and guarantee delivery within 5 days.
1. High technical barriers: P29 is a 29-amino-acid polypeptide prone to inclusion body formation during recombinant expression, bringing great challenges to refolding and purification. The yield under high purity conditions is only around 50%.
2. Stringent quality standards: Control of endotoxin, host protein and bacteriophages requires full-process sterile operation and dedicated chromatography systems, which conventional production lines cannot satisfy.
3. Conflict between confidentiality and production capacity: Exclusive production lines demand heavy investment and are scarce domestically; most manufacturers are unwilling to schedule separate production for small-batch customization.
4. Complex compliance documents: FDA DMF, EMA CEP and ICH Q3 impurity research materials are required, while most domestic manufacturers lack complete document systems.
HiSiaddi screened 3 top domestic polypeptide enterprises with FDA DMF filings, 3,000 L fermentation scale and sterile GMP workshops, and ultimately finalized Chongqing Paijin Biotechnology (P29 with FDA DMF filing No. 039617). We coordinated an independent 3,000 L fermenter, exclusive purification line and sterile lyophilization area, and signed a Non-Disclosure Agreement (NDA) to ensure process confidentiality and avoid co-production.
HiSiaddi collaborated with the manufacturer’s technical team to conduct four major optimizations tailored to client requirements:
1. Fermentation optimization: Engineered E. coli strains, optimized induction temperature and duration to raise soluble expression rate to 85% (vs. conventional 60%) and reduce inclusion body formation.
2. Purification upgrade: Adopted exclusive three-step chromatography (ion exchange + reversed-phase + gel filtration) with replacement of conventional packing materials, controlling single impurity ≤0.08%, total impurities ≤0.4% and achieving 99.6% purity.
3. Sterility & endotoxin control: Full-process operation in Class A clean areas, dedicated 316L electrolytically polished chromatography systems and 0.22 μm sterile filtration cartridges, stabilizing endotoxin below 0.08 EU/mg.
4. Customized lyophilization: Optimized pre-freezing, sublimation and desorption parameters to produce loose sterile lyophilized powder with ≥24 months stability at -20°C, meeting long-term storage demands.
HiSiaddi’s compliance team coordinated with the manufacturer to compile full sets of documents complying with FDA/EMA standards:
1. DMF documents: Updated P29 DMF with supplementary customized process, quality control and stability data.
2. COA & test reports: Full English COA, HPLC chromatograms, Mass Spectrometry (MS), Nuclear Magnetic Resonance (NMR), endotoxin, host protein and bacteriophage test reports for each batch.
3. Process Validation (PV): Completed continuous production validation of 3 batches, providing process parameters, purity/impurity stability and yield data to support client FDA audits.
4. Batch traceability: Established a full-chain traceability system spanning strain to finished product, enabling full traceback of fermentation records, chromatography data and lyophilization parameters for every batch.
1. Production scheduling: Priority production on exclusive lines split into two batches of 25 kg each to eliminate cross-contamination risks.
2. Quality monitoring: HiSiaddi assigned full-time QA staff stationed at the factory to supervise fermentation, purification, lyophilization and packaging throughout the process, synchronizing quality data every 24 hours.
3. Customized packaging: 1 kg sterile vials with aluminum plastic caps, light-shielded aluminum bags and cold-chain foam boxes equipped with temperature recorders for full -20°C cold-chain transportation.
4. Delivery execution: Production and inspection of the first 50 kg batch finished in 42 days, delivered 3 days ahead of schedule with complete consistent batch documents and fully compliant quality indicators.
· Purity: 99.6% (client requirement ≥99.5%)
· Single impurity: 0.07% (threshold ≤0.1%)
· Endotoxin: 0.06 EU/mg (threshold <0.1 EU/mg)
· Host protein: 8 ng/mg (threshold <10 ng/mg)
· Sterility / bacteriophage: Not detected
· Stability: No purity decline or impurity growth after 6-month accelerated stability testing
The client submitted DMF, COA and PV reports to the FDA, passing pre-review in one round with zero deficiencies, directly supporting New Drug Application (NDA) for semaglutide analogs.
· Cost: 35% lower than European suppliers (eliminating the 40% premium)
· Lead time: Delivery in 42 days (client target 45 days), 18 days shorter than domestic conventional cycles
The client’s R&D director commented: "HiSiaddi is our most trusted Chinese partner for biopharmaceutical customization. It accurately interpreted our high-end customized demands, rapidly secured exclusive production capacity, broke through technical barriers for high purity and low endotoxin, and delivered FDA-compliant customized P29 in 42 days with complete documents and stable quality, thoroughly resolving our European supply chain bottlenecks."
Based on this cooperation, the client signed a 5-year exclusive customization agreement with HiSiaddi, raising annual procurement volume to 200 kg. The client also entrusted HiSiaddi with customized development of 5 high-end intermediates including semaglutide side chains and GLP-1 receptor agonist fragments, establishing a global strategic partnership.
For overseas high-end pharmaceutical enterprises sourcing high-end polypeptide intermediates such as P29, core customization barriers include ultra-high purity, ultra-low endotoxin, sterile customization, process confidentiality and complete compliance documentation. European suppliers face high costs and insufficient capacity, while regular domestic manufacturers cannot simultaneously satisfy high-end quality and customized requirements, restricting clients’ supply chains and delaying R&D progress.
With precise demand interpretation, mature high-end manufacturer resources, professional process optimization capabilities and a comprehensive compliance service system, HiSiaddi delivers one-stop solutions for high-end customization through a workflow of securing exclusive GMP production lines → customized process development → full-chain compliance documentation → flexible production and delivery:
1. Technical breakthrough: Optimized fermentation and purification processes to achieve 99.6% ultra-high purity and ultra-low endotoxin, surpassing client expectations.
2. Production capacity guarantee: Coordinated exclusive production lines to deliver products in 42 days, shortening R&D cycles.
3. Closed-loop compliance: Custom FDA/EMA-standard documents passed pre-review in one round to support new drug filings.
4. Cost optimization: 35% cost reduction vs. European suppliers, balancing quality and expenditure.
5. Deepened trust: Professional, efficient and confidential customized services secured long-term exclusive cooperation with high-end clients.
This service not only realized customized mass production of P29 but also set a benchmark for HiSiaddi, a Chinese enterprise, serving global top biopharmaceutical enterprises with high-end customized solutions. It facilitates high-end domestic polypeptide intermediates to accurately access the global innovative drug market and break the monopoly of European and American supply chains.
For further customized service inquiries, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
